236 related articles for article (PubMed ID: 30383494)
1. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
2. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
3. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
4. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
5. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
6. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
7. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
Tian T; Kou Y; Huang R; Liu B
Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
[TBL] [Abstract][Full Text] [Related]
8. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
Rosario PW; Mourão GF; Calsolari MR
Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
[TBL] [Abstract][Full Text] [Related]
9. Papillary thyroid cancer: medical management and follow-up.
Kloos RT
Curr Treat Options Oncol; 2005 Jul; 6(4):323-38. PubMed ID: 15967085
[TBL] [Abstract][Full Text] [Related]
10. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy.
Landenberger GMC; de Souza Salerno ML; Golbert L; de Souza Meyer EL
Horm Metab Res; 2021 Feb; 53(2):94-99. PubMed ID: 32886943
[TBL] [Abstract][Full Text] [Related]
13. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
14. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
[TBL] [Abstract][Full Text] [Related]
15. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
16. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
17. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
18. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
19. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
Ramos da Silva F; Rosario PW; Mourão GF
Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
[TBL] [Abstract][Full Text] [Related]
20. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
